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Improved antigenicity against HIV-1 envelope (Env) protein is needed to elicit vaccine-
induced protective immunity in humans. Here we describe the first tests in non-human pri-
mates (NHPs) of Env gp140 protein fused to a humanized anti-LOX-1 recombinant antibody
for delivering Env directly to LOX-1-bearing antigen presenting cells, especially dendritic
cells (DC). LOX-1, or 1ectin-like oxidized low-density lipoprotein (LDL) receptor-1, is
expressed on various antigen presenting cells and endothelial cells, and is involved in pro-
moting humoral immune responses. The anti-LOX-1 Env gp140 fusion protein was tested
for priming immune responses and boosting responses in animals primed with replication
competent NYVAC-KC Env gp140 vaccinia virus. Anti-LOX-1 Env gp140 vaccination elic-
ited robust cellular and humoral responses when used for either priming or boosting immu-
nity. Co-administration with Poly ICLC, a TLR3 agonist, was superior to GLA, a TLR4
agonist. Both CD4+ and CD8+ Env-specific T cell responses were elicited by anti-LOX-1
Env gp140, but in particular the CD4+ T cells were multifunctional and directed to multiple
epitopes. Serum IgG and IgA antibody responses induced by anti-LOX-1 Env gp140 against
various gp140 domains were cross-reactive across HIV-1 clades; however, the sera
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neutralized only HIV-1 bearing sequences most similar to the clade C 96ZM651 Env gp140
carried by the anti-LOX-1 vehicle. These data, as well as the safety of this protein vaccine,
justify further exploration of this DC-targeting vaccine approach for protective immunity
against HIV-1.
Introduction
The RV144 Thai HIV vaccine trial gave some hope that protective immunity could be evoked
by a combination of priming via a viral vector with HIV Env protein plus adjuvant as a boost.
However, vaccine efficacy was modest at 60% at year 1 and waned rapidly [1,2]. Thus, current
preventative HIV vaccine development efforts are focused on optimizing such priming and
boosting components and investigating vaccination regimens. An approach to increasing pro-
tein antigen efficacy is their selective delivery to endocytic receptors on dendritic cell (DC)
surfaces, the key cell type for initiating and regulating immune responses [3]. Indeed, immuni-
zation of nonhuman primates (NHPs) with an anti-DEC-205 antibody fused to HIV Gag p24
followed by a boost with recombinant New York vaccinia (NYVAC) virus bearing p24 induced
robust T cell and humoral immunity [4]. However, antibody responses directed to the HIV-1
coat protein Env are key to protective humoral responses. To this end, we have developed as a
candidate protein a DC-targeting vaccine bearing gp140 from clade C 96ZM651 fused to a
humanized anti-human LOX-1 recombinant IgG4 antibody, termed αLOX-1.Env gp140.
LOX-1, or lectin-like oxidized low density lipoprotein receptor, is a C-type lectin pattern recog-
nition receptor, and in vitro and in vivo studies show that targeting antigens to LOX-1 instructs
DCs and B cells to promote the generation of mucosal plasmablast differentiation as well as
eliciting CD4+ T cell responses with a Th1 phenotype [5,6], thus making it an attractive candi-
date endocytic receptor for targeting Env protein.
Our study tests the relative efficacy of antibody and T cell responses directed to Env gp140
in NHPs vaccinated with αLOX-1.HIV Env gp140 co-administered with either poly ICLC
(Toll-like receptor 3 or TLR3 agonist) or Glucopyranosyl Lipid Adjuvant (GLA, TLR4 agonist)
as adjuvants and vaccine assessment was conducted in animals either primed or further
boosted with a replication-competent viral vector (NYVAC-KC) bearing Env gp140 and Gag-
PolNef. We found that the αLOX-1.Env gp140 fusion protein elicited robust anti-Env serum
antibody responses, either as a prime or in boosting viral-based vaccination. The combination
of αLOX-1.Env gp140 with poly ICLC was particularly favorable for both antibody and T cell
responses to Env gp140.
Results
Characteristics of anti-LOX-1 antibody fused to Env gp140 protein
We humanized the mouse variable regions of the previously described anti-human LOX-1
(αLOX-1) recombinant human IgG4 antibody vehicle that elicited protective humoral immu-
nity in NHPs against Influenza virus when fused to influenza haemagglutinin HA1 [5,6]. Clade
C 96ZM651 Env gp140 sequence was fused to the heavy (H) chain C-terminal codon and
αLOX-1.Env gp140 protein was purified by protein A affinity chromatography from CHO-S
cells stably transfected with vectors encoding αLOX-1.Env gp140 H chain and αLOX-1 L chain
(Fig 1A). The product was heavily glycosylated based on reducing SDS-PAGE analysis (Fig
1B). Analysis of the protein complex by size exclusion chromatography showed that αLOX-1.
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Env gp140 forms a homogenous species with a peak size of ~500 kDa, which is consistent with
the expected configuration of one antibody (ca. 150 kDa) plus two gp140 molecules. Thus,
the dimerization of the antibody is dominant over the trimerization capacity of Env, and no
higher-order complexes (such as minimally three antibody-dimers plus two gp140 trimers) are
formed (Fig 1A–1C). αLOX-1.Env gp140 bound to human LOX-1 ectodomain protein equiva-
lently compared to the parental recombinant antibody without fused antigen (Fig 1D) and
retained cross-reactivity to NHP LOX-1 [5] (and not shown). Importantly, αLOX-1.Env gp140
maintained reactivity against a panel of neutralizing anti-Env antibodies that recognize distinct
epitopes, although these interactions varied via both increased and decreased affinity compared
to control trimeric 96ZM651 Env gp140 protein (S1 Table), suggesting minor distortions rather
than abrogation of natural gp140 epitopes.
Fig 1. Design and physical properties of αLOX-1.Env gp140 fusion protein. (A) Schematic representation showing antibody (grey) fused at the H chain
C-terminus to HIV Env gp140 (black). (B) Analysis of 3 μg purified αLOX-1.Env gp140 fusion protein (lane 2) or 3 μg purified αLOX-1 protein (lane 3) by
reducing SDS-PAGE stained with Coomassie Blue and location of protein molecular weight markers (lane 1) is indicated in kDa. Unglycosylated mass of
αLOX-1 L chain is ca. 23,800 Da and of αLOX-1.Env gp140 H chain is ca. 127,570 Da. (C) Size exclusion gel chromatography analysis of αLOX-1.Env
gp140. The proteins were run separately on an TSKG4000SW column in PBS at 0.5 ml/min. αLOX-1.Env gp140 is shown in the solid line, trimeric gp140 is
shown in the dashed line, and monomeric gp140 is shown in the dotted line. For molecular weight calibration the NativeMark Protein Standard (Life
Technologies, LC0725) was used and their peak positions are indicated. (D) Equilibrium competition binding analysis of αLOX-1.HIV Env gp140 interaction
with human LOX-1. Beads coated with human LOX-1 ectodomain were incubated overnight with 10 ng/ml of the parental mouse αLOX-1 mAb and varying
concentrations of αLOX-1.Env gp140 or humanized αLOX-1 IgG4 without fused antigen (X axis units are nM competing human αLOX-1 proteins), then
probed with PE-labeled anti-mouse IgG, and analyzed by flow cytometry (Y axis units are mean fluorescence intensity). Black circles are an irrelevant control
human IgG4 mAb, grey squares are human αLOX-1.Env gp140, and vertical strokes are humanized αLOX-1 without fused antigen.
doi:10.1371/journal.pone.0153484.g001
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αLOX-1.Env gp140 elicits Env-specific antibody responses in NHPs
The overall study design is shown in Table 1. In groups 1 and 2 (G1, G2), naïve Rhesus
macaques were primed by two intramuscular (i.m.) injections, one month apart, containing
108 pfu of separate replication competent NYVAC-KC viruses encoding: i) clade C 96ZM651
Gag with C/B’ clade 97CN54 PolNef, and ii) clade C 96ZM651 Env gp140 sequences [7]. Two
months later, the NHPs were immunized three times monthly with 250 μg αLOX-1.Env gp140
injected intradermally (i.d.) in 8 sites around a single subcutaneous (s.c.) site administered with
either Poly ICLC (G1; Hiltonol, 1 mg), a formulated TLR3 agonist, or GLA (G2; GLA, 20 μg), a
synthetic TLR4 agonist. Ten weeks later, the NHPs in all groups were boosted with an addi-
tional i.m. injection of the NYVAC-KC viruses.
The table shows the immunization regimens used in this study. NYVAC-KC is a mixture of
replication competent viruses encoding: i) HIV B/C clade CN54 PolNef with clade C 96ZM651
Gag, and ii) clade C 96ZM651 Env gp140 sequences. Poly ICLC and GLA are co-administered
adjuvants. Week refers to sample times calculated from initiation of the study (Week 0). For
clarity, the groups are referred to as G1 Nkc2Lp3Nkc, G2 Nkc2Lg3Nkc, G3 Lp3Nkc, and G4
Lg3Nkc.
Serum Env-specific IgG levels from G1 Nkc2Lp3Nkc and G2 Nkc2Lg3Nkc were undetect-
able or very low after the NYVAC-KC injections through to the first αLOX-1.Env gp140
administration at week 12 (Fig 2A). However at week 14, two weeks after the first αLOX-1.Env
gp140 injection, serum Env-specific IgG titers were readily detected in all NHPs. The two sub-
sequent injections of αLOX-1.Env gp140 further boosted titers, which had waned somewhat
from the peaks at 2 weeks after each injection. Maximal titers were achieved at week 22, two
weeks after the third αLOX-1.Env gp140 injection (P = 0.016 for both comparison to baseline;
Wilcoxon signed-rank tests), and there was no significant difference between αLOX-1.Env
gp140 adjuvanted with poly ICLC versus GLA (tested Relative to a Random Effect Model,
P = 0.7). Eight weeks after the observed peak at week 22, titers again decreased and were not
boosted by the additional NYVAC-KC administration at week 30. However, the magnitude of
IgG responses remained higher than baseline values (P = 0.016 for both groups).
NHP groups G3 Lp3Nkc and G4 Lg3Nkc received placebo instead of NYVAC-KC at weeks
0 and 4 (Table 1). Undetectable or very low serum anti-Env titers were present until two weeks
after the second αLOX-1.Env gp140 administration (week 16), but were boosted to maximal
values two weeks after the third αLOX-1.Env gp140 administration (week 22) (P = 0.06 in both
groups as compared to baseline values), especially in G3 with poly ICLC as adjuvant (Fig 2A).
Week 22 peak titers waned through to week 30, but were boosted by a single NYVAC-KC
injection at week 30 in both groups. For G3 versus G4, there was a significant advantage for the
poly ICLC adjuvant versus GLA adjuvant at week 22, but there was no difference in the boost
from the NYVAC-KC administration at weeks 32 and 34 (respectively, P = 0.02, P = 0.68, and
P = 0.88; Wilcoxon Rank Sum Test).
Table 1. Study design for testing immunogenicity of αLOX-1.Env gp140 in NHP.
Group Size Week 0 Week 4 Week 12 Week 16 Week 20 Week 30







2 Nkc2Lg3Nkc 6 NYVAC-KC NYVAC-KC αLOX-1.gp140 ⁄ GLA αLOX-1.gp140 ⁄ GLA αLOX-1.gp140 ⁄ GLA NYVAC-KC







4 Lg3Nkc 4 Placebo Placebo αLOX-1.gp140 ⁄ GLA αLOX-1.gp140 ⁄ GLA αLOX-1.gp140 ⁄ GLA NYVAC-KC
doi:10.1371/journal.pone.0153484.t001
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At weeks 22 and 32 sera from all four NHP groups were tested for Env-specific IgG titers
against Env gp120 and gp41 subdomains. All groups raised serum titers specific to both the
gp120 and gp41subdomains of Env gp140 (S1 Fig).
Sera from all four NHP groups were also tested for Env-specific IgG titers against a wider
array of HIV-1 Env antigens including clade C.1086V1-V2 Tags, Con S gp140 CFI (a group M
consensus envelope gp140), clade A 00MSA 4076 gp140 (Fig 3A–3D), and A1.con.env03 140
CF (clade A Consensus), B.con.env03 140 CF (clade B Consensus), C.con.env03 140 CF (clade
C Consensus), JRFL gp140 (clade B), gp70 control, and gp70_B.CaseA2 V1/V2 (not shown).
Sera from the week 22 and week 32 samples gave positive IgG response rates to all the Env pro-
teins to those observed against the clade C 96ZM651 Env gp140 protein that was vaccinated
sequence (Fig 3A). At week 22, cross-clade IgG binding antibody responses were detected in all
Fig 2. Serum Env gp140-specific IgG responses to αLOX-1.Env gp140 administration. (A) Responses in NHP (n = 6 per group) primed with NYVAC-KC
virus at week 0 and week 4 (X axis values), followed by αLOX-1.Env gp140 administrations at weeks 12, 16, and 20, with an additional NYVAC-KC boost at
week 30 are shown. (B) Responses in NHP primed with αLOX-1.Env gp140 administrations at weeks 12, 16, and 20 (n = 4 per group), with a NYVAC-KC
virus boost at week 30 are shown. Open symbols are with poly ICLC co-administration and closed symbols are with GLA co-administration. Reciprocal of the
half maximal titration by solid-phase ELISA versus Env gp140 protein is plotted for individual NHPs. Bars are the median. Response rates, based on 1/EC50
>2, are shown above the X-axis and are 100% unless otherwise indicated.
doi:10.1371/journal.pone.0153484.g002
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Fig 3. Analysis of Env binding serum IgG antibody titers. Plasma samples taken at week -2 (baseline), week 22 (2 weeks post αLOX-1.Env gp140
vaccinations), and week 32 (2 weeks post NYVAC-KC boost) were measured by binding antibody multiplex assay against the indicated Env proteins: (A)
96ZM651 gp140, (B) C.1086C_V1_V2 Tags, (C) Con S gp140 CFI, (D) 00MSA 4076, and (E) gp70_B.CaseA-V1_V2. Each panel shows anti-Env IgG titers
represented as an area under the titration curve (AUC) of individual NHP (n = 6 for G1, G2; n = 4 for G3, G4). Boxplots show the 25th, 50th, and 75th
percentiles of the AUC distribution for each group. Filled and open circles denote positive and negative responders, respectively, and the percent of positive
responders is noted above each boxplot. AUC comparisons between groups where theWilcoxon rank sum test p-value is < 0.05 are denoted with a *. Note
that part of the data (weeks -2, 22, 32) in (A) is replicated independently in Fig 2.
doi:10.1371/journal.pone.0153484.g003
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NHPs (Fig 3A–3D), with G1 Nkc2Lp3Nkc, G2 NkcLg3Nkc, and G3 Lp3Nkc having signifi-
cantly higher responses than G4 Lg3Nkc for most envelope proteins. G1 Nkc2Lp3Nkc IgG
responses generally trended higher than G3 Lp3Nkc, with differences noted in the clade A
gp140 protein (00MSA 4076 gp140) and clade C V1-V2 antigen (C.1086C_V1_V2 Tags)
(P<0.05, Wilcoxon Rank Sum Test). However, at week 32, IgG binding titers (AUC) trended
higher in G3 and G4 Lg3Nkc as compared to G1 and G2 Nkc2Lp3Nkc with significant differ-
ences noted for the vaccine strains gp140 (96ZM651 gp140) and Con S gp140 CFI (P<0.05,
Wilcoxon Rank Sum Test). There were no significant differences in response rates between
groups for any antigen at week 22 or 32. Thus, the magnitude of the envelope antibody
response is improved after the last NYVAC-KC immunization in the absence of NYVAC-KC
prime. At week 22, IgG binding antibody titers to most envelope proteins trended higher in G1
Nkc2Lp3Nkc compared to G2 Nkc2Lg3Nkc (Fig 3A–3D) with the clade B gp140 proteins (B.
con.env03; JRFL gp140) scoring significantly higher for G1 than G3 (P<0.05, Wilcoxon Rank
Sum Test, not shown).
Globally, serum IgA responses were lower compared to IgG binding responses (Fig 4). Bind-
ing levels were higher in the poly ICLC adjuvant groups G1 Nkc2Lp3Nkc and G3 Lp3Nkc and
there were no significant differences between these groups at week 22 or week 32 in response
rates and titers.
Analysis of HIV-1 neutralizing activity in week 22 and week 32 plasma samples was per-
formed via TZM.bl assays against a panel of Tier 1 and Tier 2 HIV-1 Env pseudotyped viruses.
Neutralizing activity was detected against MW965.26 (clade C, Tier 1A, Fig 5) and TH023.6
(CRF01_AE, Tier 1A, Fig 5). Little or no neutralization was detected against viruses MN.3 and
SF162.LS (clade B, Tier 1A), Bal.26 (clade B, Tier 1B) (S2 Table). Also, no neutralization was
detected against the clade C Tier 2 viruses TV1.21, Ce1086_B2 and 96ZM651 (S2 Table). Neu-
tralization titers against the sensitive viruses (MW965.26 and TH023.6) decreased from week
22 to week 32 in groups G1 Nkc2Lp3Nkc and G2 Nkc2Lg3Nkc, but was similar or increased in
groups G3 Lp3Nkc and G4 Lg3Nkc.
ADCC-mediated antibody responses were measured at week 0, 6, 22, and 32, but were unin-
formative due to unexplained high response rates at baseline (S2 Fig).
αLOX-1.Env gp140 elicits Env-specific T cell responses in NHP
T cell responses specific to the non-Env antigens delivered by the NYVAC-KC bearing Gag,
Pol, and Nef, as well as Env-specific T cell responses from either the NYVAC-KC bearing Env
gp140 and the αLOX-1.Env gp140 vaccine, were monitored by IFNγ ELISPOT analysis of
PBMCs. In NHP groups G1 Nkc2Lp3Nkc and G2 Nkc2Lg3Nkc, NYVAC-KC elicited signifi-
cant T cell responses against non-Env antigens (P = 0.036 for both groups at week 2 as com-
pared to baseline, Wilcoxon signed-rank tests), whereas no significant increase of responses
against Env was noted at two weeks post the second NYVAC-KC administration (Fig 6). At
week 14, 2 weeks after the first αLOX-1.Env gp140 boost, Env-specific T cells were increased
significantly (P = 0.031 as compared to baseline), while non-Env-specific T cell numbers
waned compared to their peak 2 weeks after the second virus injection. In contrast to the anti-
body responses, blood Env-specific T cell levels were maintained during the αLOX-1.Env
gp140 vaccinations, subsequently dropped by ~2-fold, and were not markedly boosted with the
additional NYVAC-KC injection. However, responses against Env and non-Env peptides
remained significantly higher than baseline values in both groups (P = 0.03). Analysis of
responses defined by separate peptide pools (not shown) indicated that both non-Env and
Env-specific T cell responses were directed to multiple epitopes. There were no significant dif-
ferences between G1 Nkc2Lp3Nkc and G2 Nkc2Lg3Nkc in the overall magnitude or epitope
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spread for the T cell responses, although the responses trended higher in the poly ICLC adju-
vanted G1.
In G3 Lp3Nkc, αLOX-1.Env gp140 co-administered with poly ICLC elicited detectable cir-
culating Env-specific T cell at 2 and 4 weeks after the first administration, the second dose
raised these levels several-fold (Fig 6). After the second vaccination, the levels waned and
Fig 4. Analysis of Env-specific IgA binding levels. Plasma samples taken at week -2 (baseline), week 22 (2 weeks post αLOX-1.Env gp140
administrations), and week 32 (2 weeks post NYVAC-KC boost) were measured by binding antibody multiplex assay against the Env proteins indicated
above each panel. Each panel shows anti-Env IgA binding units (MFI) of individual NHPs NHP (n = 6 for G1, G2; n = 4 for G3, G4). Plotting details are as
described in Fig 3, except IgA levels were log10-transformed. Non-responders (open circles) did not meet the pre-specified criteria for vaccine-induced
positivity as outlined in the Methods.
doi:10.1371/journal.pone.0153484.g004
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stabilized through week 30, but were restored to peak levels by the NYVAC-KC boost. In con-
trast, in the GLA adjuvanted G4 Lg3Nkc, αLOX-1.Env gp140 failed to elicit detectable circulat-
ing Env-specific T cells. The single virus administration at week 30 elicited moderate Env-
specific T cell counts similar to those seen in groups G1 and G3 two weeks after a single
NYVAC-KC administration (Fig 6). Analysis of responses defined by separate Env peptide
pools (not shown) indicated that Env-specific T cell responses were directed to multiple epi-
topes and there were no apparent differences between G3 Lp3Nkc and G4 Lg3Nkc in the T cell
epitope regions of the response to Env.
Intracellular cytokine staining (ICS) analysis of non-Env and Env-specific blood T cells at
week 6 (two weeks post the NYVAC-KC boost in G1 and G2) and week 22 (2 weeks post
the final αLOX-1.Env gp140 administration) revealed robust Env-specific CD4+ T cell
responses amplified from the weak responses primed by the NYVAC-KC administrations (G1
Nkc2Lp3Nkc and G2 Nkc2Lg3Nkc), or elicited in the naive NHPs (G3 Lp3Nkc and G4
Lg3Nkc) (Fig 7A). Env-specific CD8+ T cell responses were also detected in all groups. How-
ever, the Env-specific CD8+ T cell responses primed by NYVAC-KC were not amplified by
αLOX-1.Env gp140 administration (Fig 7B).
αLOX-1.Env gp140 vaccination expanded the proportion of Env-specific CD4+ T cells from
all three Env regions sampled (Fig 8A), however, it had little effect on the specificity of the
CD8+ T cell responses (Fig 8B). Antigen-specific T cell quality was appraised by intracellular
production of IFNγ, TNFα, and IL-2. Quality was high (2–3 cytokines) for the CD4+ T cells in
G1 Nkc2Lp3Nkc ands G2 Nkc2Lg3Nkc, both after the NYVAC-KC administrations and the
αLOX-1.Env gp140 boosts (Fig 8C). For G3 Lp3Nkc and G4 Lg3Nkc, CD4+ T cell quality was
high after the αLOX-1.Env gp140/ poly ICLC administrations, but low with αLOX-1.Env
Fig 5. Analysis of neutralizing antibody titers. Plasma samples taken at peak response week 22 (2 weeks post αLOX-1.Env gp140 administrations) and
week 32 (2 weeks post NYVAC-KC boost) for groups 1–4 (G1-G4) were tested for neutralizing titers versus each indicated virus (MW965.26 or TH023.6).
Log to base 10 of titers inhibiting replication by 50% for individual NHP (n = 6 for G1, G2; n = 4 for G3, G4) are shown. Boxes represent the middle 95th
percentile. Horizontal lines are the median. S2 and S3 Tables show similar tests against other viruses.
doi:10.1371/journal.pone.0153484.g005
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gp140/ GLA administrations. Quality was low to moderate (1–2 cytokines) for the HIV-specific
CD8+ T cells in all groups (Fig 8D).
Discussion
Amilestone in the field of preventative HIV-1 vaccine was achieved with the reports of the
RV144 trial, which evaluated a regimen consisting of a replication-defective vaccinia vector in
combination with a recombinant gp120 protein in over 16,000 heterosexual men and women
Fig 6. Analysis by IFNγ ELISPOT of blood T cell responses.Reponses in NHP in the indicated NHP groups (n = 6 for G1, G2; n = 4 for G3, G4) are shown
averaged for each group for each sampling time (shown in the X axis as weeks relative to initiation of the vaccinations). Filled points are the sum of T cell
responses specific to 6 peptide pools for Gag, Pol, and Nef (i.e., responses to NYVAC-KC Gag Nef Pol), while open points are summed averages of T cell
responses specific to Env gp140 peptide pools (i.e., response to NYVAC-KC Env gp140 and/or αLOX-1.Env gp140). Medians for each group at each
sampling time are presented and bars are the quartile 25–75 range. Arrows below the X-axis indicate the time points for NYVAC-KC (Nkc) and the DC-
targeting vaccinations with poly ICLC (Lp) or GLA (Lg).
doi:10.1371/journal.pone.0153484.g006
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in Thailand [8,9]. This regimen demonstrated a statistically significant, albeit modest, reduc-
tion in HIV-1 acquisitions. While the first year vaccine efficacy (VE) approached 60%, this
waned over time and overall VE over the 3.5 years of the trial was 31.2% [2].
Following these results, development of preventative vaccines against HIV-1 infection is
focused on eliciting long-lasting humoral responses directed to the envelope protein. The
desired properties of Env-specific antibodies likely include high affinity binding directed to rel-
atively conserved regions of Env that are critical for cellular entry, and/or antibodies with
ADCC properties to lyse infected cells.
While the RV144 study has shown that neutralizing antibodies were uncommon in pro-
tected individuals, essentially all RV144 vaccine recipients developed binding antibodies to
gp120. Vaccinees with the highest levels of binding V1V2 antibodies were more likely to be
protected than those with lower antibody levels [1,10,11,12]. Interestingly, the titer of these
V1V2 antibodies waned over time in temporal association with the waning protective efficacy
[12]. V1V2 antibodies were not broadly neutralizing but rather mediated ADCC and additional
analyses showed the importance the IgG isotype, demonstrating that IgG3 antibodies had
higher ADCC [12] while binding IgA Env antibodies were modestly associated with decreased
vaccine efficacy [1,13]. However, evoking concomitant CD4+ T cell responses against Env or
other HIV-1 proteins such as Gag [14] is also desired as helper CD4+ T cells can produce effec-
tor proteins to hinder infection and are essential for driving effective B cell responses, while
cytotoxic CD8+ T cells can complement ADCC. This has been demonstrated in follow up anal-
yses of the RV144 case-control data, where poly-functionality in CD4+ ENV-specific T cells
was shown to be inversely correlated with infection risk [15].
It is likely that future success for HIV-1 vaccine development will rest on a prime-boost reg-
imen of viral or DNA-based vectors encoding Env combined with other HIV-1 proteins for
priming and Env protein as boost [16]. Questions addressing the exact nature of the Env
sequence components enabling development of broadly neutralizing antibodies, the most
Fig 7. Analysis of HIV Env-specific cytokine-producing T cells. (A) Env peptide-specific CD4+ T cell responses and (B) Env peptide-specific CD8+ T cell
responses from PBMC samples taken at week 6 (2 weeks post NYVAC-KC administration for G1 and G2 only) (blue circles) and week 22 (2 weeks post the
final αLOX-1.Env gp140 administration) (red circles). The data are based on total CD4+ and CD8+ T cells and show the sum of IFNγ+, IL-2+, and TNFα+ T
cells specific to the Env peptide pools for individual NHP as filled circles. The grey horizontal bars are the median value for the group NHP (n = 6 for G1, G2;
n = 4 for G3, G4) and the vertical grey bars are the IQR.
doi:10.1371/journal.pone.0153484.g007
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Fig 8. Analysis of HIV-specific T cell responses. The upper pie charts show the percentage of epitope specificities for (A) CD4+ T cell responses and (B)
CD8+ T cell responses from PBMCs sampled at week 6 (2 weeks post NYVAC-KC administration, NHP groups G1 and G2 only) and week 22 (2 weeks post
αLOX-1.Env gp140 administration) as defined by IFNγ+ T cells specific to each peptide pool. The lower pie charts show analysis of multifunctional HIV-
specific T cell responses. ICS analysis of HIV-specific (C) CD4+ (left 6 pies) and (D) CD8+ (right 6 pies) T cells in PBMC samples taken at week 6 (2 weeks
post NYVAC-KC administration, G1 Nkc2Lp3Nkc and G2 Nkc2Lg3Nkc only) and week 22 (2 weeks post αLOX-1.Env gp140 administration). The data show
the breakdown of IFNγ+ (labeled as G), IL-2+ (labeled as 2) and TNFα+ (labeled as T) T cells specific to the combined HIV peptide pools (n = 6 NHP for G1,
G2; n = 4 NHP for G3, G4). The lower linear presentation in (C) and (D) shows the same data as the pie charts, but includes data points for individual NHPs.
doi:10.1371/journal.pone.0153484.g008
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potent adjuvants for Env protein administration, as well as the best regimen for the prime and
the boost, are currently under investigation. Directing HIV-1-specific responses to the mucosal
sites of primary infection is also essential for prevention of infection. Finally, in the RV144
study, the titers of anti V1V2 binding antibodies waned over time in association with the loss
of protective efficacy suggesting that the vaccine strategy did not induce durable immune
responses.
An unexplored vaccination approach is potential enhancement of humoral and cellular
response directed to Env via targeting it to dendritic cells (DCs) with antibody vehicles specific
for endocytic DC receptors. Here we present the first study in the NHP model of the efficacy of
directing Env to LOX-1 expressed on various antigen-presenting immune cells, including DCs.
We tested as an Env protein vaccine component αLOX-1.Env gp140 (clade C 96ZM651) adju-
vanted with either poly ICLC or GLA in NHP in prime-boost combinations with NYVAC-KC,
an attenuated vaccinia virus bearing HIV-1 Env gp140 (clade C 96ZM651) mixed with virus
bearing Gag Pol and Nef. We chose to target Env to LOX-1 based on in vitro studies showing
targeting to LOX-1 instructs DCs and B cells to promote mucosal plasmablast differentiation
and elicits CD4+ T cell responses with a Th1 phenotype [5,6], as well as a pilot NHP study
showing protective antibody responses to αLOX-1 vaccine bearing Influenza haemagglutinin
[17].
Twice administered NYVAC-KC evoked low-level humoral immunity specific to Env and
modest cellular responses specific to Env/Gag/Nef/Pol. A single boost with αLOX-1.Env gp140
combined with either poly ICLC or GLA was very effective in amplifying both anti-Env anti-
body and mixed CD4+/CD8+ T cell responses. Repeated αLOX-1.Env gp140 immunization
favored the antibody response compared to the cellular response. The effectiveness of repeated
αLOX-1.Env gp140 doses indicates that circulating antibodies directed either to Env or to the
vehicle IgG4 component do not negate the action of the vaccine (also documented in reference
[18]). In contrast, the NYVAC-KC boost following αLOX-1.Env gp140 administrations in
primed animals had little discernable impact on humoral or cellular immunity directed to Env,
possibly due to development of immunity to the vaccinia vector.
αLOX-1.Env gp140 administration in naïve NHP required two doses to elicit significant
anti-Env gp140 humoral responses, with maximal observed responses after the third dose. Poly
ICLC was moderately more effective than GLA for this antibody response, and helped raise
modest antigen-specific serum IgA responses. Also, poly ICLC was clearly superior to GLA for
evoking cellular immunity. In poly ICLC adjuvanted G3 Lp3Nkc NHPs, NYVAC-KC adminis-
tration restored the cellular response to the peak level seen after the second αLOX-1.Env gp140
administration. These data indicate that αLOX-1.Env gp140 combined with poly ICLC is an
efficient prime for NYVAC-KC boost.
Vaccine adjuvants based mainly on activators of innate immunity via TLR engagement are
well studied, particularly in mice (reviewed in [19]), but direct comparisons of their efficacy in
NHP versus man are limited. This is important since there are key differences in TLR distribu-
tion and action between mouse and man (see e.g., for TLR4 in [20]), but seeming concordance
between `NHP and man (L. Su, personal communication). Poly IC, a synthetic analog of
dsRNA recognized by TLR3, was previously shown to be effective for increasing antibody and
CD4+ T cell responses against protein vaccines in NHP in both priming and viral boost settings
[4,21,22]. GLA, a synthetic TLR4 agonist, which may have advantage in the setting of human
intradermal injection [23] has previously proven to be effective in NHP for evoking humoral
and CD4+ T cell immune responses against a malarial protein [24], and humoral immunity
against Env in NHPs [25]. Our data for protein vaccine adjuvanted with poly ICLC are concor-
dant with previous studies (above references and [5]), however the striking lack of T cell
responses in naïve NHP administered with αLOX-1.Env gp140/GLA suggests negative
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interplay between antigen targeted to LOX-1-bearing APCs and direct or local indirect action
of TLR4 stimulation. Mechanistic studies of antigen uptake and DC mobilization in the NHP
dermal environment will help explore this phenomenon (see e.g., [18]).
The magnitude of vaccine-induced humoral and cellular responses is important, but their
quality and longevity need to be sufficient to mount protective immunity. In this context, anal-
ysis of sera from peak response time points revealed similar data for all groups regarding the
cross-reactivity and epitope breadth of Env-specific antibodies. The neutralizing antibody
response was modest in magnitude and confined to sensitive clade C and AE viruses. In future
studies mixed or sequential vaccinations with other HIV Env clade sequences should be inves-
tigated to circumvent this issue [25]. Importantly, CD4+ T cell quality at the peak response
times was high, with breadth of epitopes across Env and ability to produce multiple effector
cytokines. CD8+ T cell responses were elicited, but were somewhat less in magnitude and
quality than CD4+ T cell responses. Similar to other observed vaccine-induced Env-specific
humoral responses in NHP, serum IgG levels waned significantly over the 8-week observation
period [26,27]. However, it is promising that in G3 Lp3Nkc and G4 Lg3Nkc NHPs the
NYVAC-KC boost, akin to HIV-1 infection of a Env-protein vaccinated individual, rapidly
restored high serum anti-Env IgG levels. Serum Env-specific IgA responses to αLOX-1.Env
gp140, which is expected based on the role of LOX-1 in directing immunity to the mucosa [6],
were observed but the expected protective potential of these antibodies is uncertain given the
correlation of certain serum HIV-1-specific IgA responses with decreased vaccine efficacy in
the RV144 trial [1].
An important issue not addressed in our present study is the relative efficacy of LOX-1-tar-
geted Env versus non-targeted Env. However, a recent study [28] in Rhesus macaques used a
similar protocol of two NYVAC-KC Env gp140 + GagPolNef administrations boosted by two
administrations of gp120 protein at a similar molar dose (100 μg) to our study. Although the
clade C gp120 sequences and adjuvant used were different, i.e., a mixture of TV1 gp120 with
MF59 adjuvant and 1086 gp120 with alum (P), the immune monitoring assays were standardized
across these two studies. In the closest matched groups of these two studies, a comparison
between serum Env-specific antibody levels at the peak response times (G1 Nkc2Lp3Nkc, week
22 and [28] G1 Nkc2(NkcP)2, week 26) showed slightly weaker but very comparable (well within
a mean difference of log10 magnitude) IgG responses against six tested Env antigens. Also, the
HIV-1 neutralization titers at peak response times in these two groups were similar [28].
Further studies exploring lower dose ranges, longevity of responses, alternate routes of
administration, and direct tests of viral challenge will be required to explore the possible bene-
fits of αLOX-1.Env gp140 over non-targeted Env protein. Evaluation of Env-specific rectal
and other mucosal IgA and IgG was not included in this study, but should be a component of
future studies. The effect of targeting Env to other DC receptors is also unexplored, as is the
possibility of increased breadth of neutralizing antibody development via targeting different
Env sequences or forms, either concurrently or staged. Importantly, αLOX-1.Env gp140
administered with either GLA or poly ICLC adjuvant in both priming and boosting settings
did not elicit adverse reactions in the NHPs. Demonstration of safety and efficacy in NHP is an
essential step for justifying clinical development of αLOX-1.Env gp140.
Materials and Methods
Ethics statement
Twenty male Rhesus macaques ranging in age from 3 to 6 years and weighing at least 4 kg were
procured from Harlan Laboratories and housed at the Advanced Biosciences Laboratories
(ABL) animal facility in Rockville, Maryland. The ABL in vivo facility is USDA-registered and
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accredited by the American Association for the Accreditation of Laboratory Animal Care
International (AAALAC). ABL’s veterinary practices comply with all policies of the "Guide for
the Care and Use of Laboratory Animals," DHHS (NIH 85–23), Animal Welfare (DHHS-TN
73–2) the NIHManual Issuance 4206 and 6000-3-4-58, "Responsibility for Care and Use of
Animals CDC/NIH 4th edition”, “Biosafety in Microbiological and Biomedical Laboratories,”
and Public Health Service Policy on Humane Care and Use of Laboratory Animals under a
Category 1 assurance from OLAW. All procedures were carried out under Ketamine anesthesia
by trained personnel under the supervision of veterinary staff and all efforts were made to ame-
liorate the welfare and to minimize animal suffering in accordance with the “Weatherall report
for the use of non-human primates” recommendations. Other than for a seven-day post-inocu-
lation follow up observation period, animals were pair-housed in adjoining primate cages
allowing social interactions, under controlled conditions of humidity, temperature and light
(12-hour light/12-hour dark cycles). Food and water were available ad libitum. Animals were
monitored and fed standard laboratory rations twice daily. Trained personnel offered dietary
supplements with fresh fruit and occasional treats at least once a day. The ABL primate envi-
ronmental enrichment program aims to promote the psychological and physiological well
being of non-human primates, including engagement in species-typical behavior. They are met
through the following strategies:
i) Social enrichment through group housing; ii) sensory and cognitive enrichment through
a novel food program, auditory and visual enrichment through presentation of approved
music and visual stimuli plus distribution of foraging or novel toys/devices; iii) identification of
and individualized treatment for psychological distress; iv) specialized enrichment for infants
and juveniles and other special considerations; v) training to reduce or eliminate stress during
human-animal interactions; and vi) program evaluation and documentation of daily assess-
ments conducted by husbandry staff and quarterly behavioral assessments performed by the
Program Veterinarian. Early endpoint criteria, as proposed by the project team and approved
by the IACUC, were used to determine when animals should be humanely euthanized. The
ABL veterinarian was authorized to determine whether animals met such criteria and if neces-
sary, was tasked to stabilize any affected animals prior to consulting with the lead investigators.
Criteria for determining the moribund state include: animal is unable to reach readily available
food or water; animal shows no reaction to external stimulus; a serious fracture has occurred
where the Veterinarian feels the pain cannot be controlled; normal bodily functions are prohib-
ited by a tumor, ascites or infection; paralysis has occurred and recovery is unlikely; animal
responds to severe pain/infection/inflammation by becoming anorexic and is unresponsive to
medical treatment; presence of tissue necrosis and/or drainage which is not responsive to medi-
cal treatment; extreme body temperatures that cannot be controlled; signs of severe organ or
system involvement; greater than 20% weight loss or chronic, uncontrollable diarrhea. The
only additional endpoints outside of moribund sac and listed in the IACUC protocol were pos-
sible anaphylaxis which would have been treated by the Veterinarian. All animals in this study
were euthanized at the protocol conclusion, following the current AVMA Guidance on Eutha-
nasia, which was conducted by an overdose of intravenous sodium pentobarbitol. ABL’s Insti-
tutional Animal Care and Use Committee (IACUC) approved of the proposed study prior to
the initiation of any in vivo work. The protocol number assigned by the IACUC/ethics commit-
tee that approved this study is AUP518.
Vaccination protocols
The NYVAC-KC inoculum was provided in 0.2 ml aliquots as NYVAC-KC expressing Envgp140
(ZM96) and ZM96gag plus CN54polnef at 0.1 ml of each virus @1.2x108pfu per vial. The
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immunogen mixture according to molar ratios was Env:GagPolNef = 1: 1. Prior to administra-
tion, the required number of vaccine vials containing the virus mixture were thawed at 37°C and
put on ice immediately after thawing. 1 ml of 1xTBS was added to each vial and briefly vortexed.
Sonication with a Bransonic 1210 unit was performed according to the following procedure: fill
water bath of the sonicator with water and ice; sonicate sample 3 times for 10 seconds each time;
after the sonication steps, vortex sample. For each animal, 1 ml of the vaccine preparation was
drawn up from the vials by a 1 ml syringe and kept on ice until administration. Before immuniza-
tion, the skin of the upper arm (deltoid) was shaved and cleaned with alcohol. Animals received
the vaccine preparation via intramuscular injection of 1 ml of the vaccine preparation @2x108
pfu/ml total of 2 viruses in the deltoid. The Poly ICLC was provided in 1 ml vials at a concentra-
tion of 2 mg/ml. Vials (Hiltonol Lot: PJ215-1-10-01) were stored at 2–8°C. Administration was 1
mg (subcutaneous) in two injections of 250 μl in the center of each circular injection pattern (3–4
cm diameter) formed by the intradermal administrations of αDCIRHIV5pep or αCD40 HIV5-
pep vaccine components which were stored in 1 M Arginine + 100 mM Tris.HCl Buffer pH 6–8.
Protein vaccine administrations were at a 200 μg dose, intradermal in a total of 8 injections of
250 μl each (2 ml total injection)—four injections will be performed in each side of the back
placed in a circular pattern. To avoid toxicity of 1 M Arginine buffer, the concentrated protein
will be diluted approximately 1:4 in PBS before use. Each animal received in the upper back (dor-
sal thoracic) a total of 8 intradermal injections of 250 μl each. Four injections were performed in
each side of the back placed in a circular pattern of 3–4 cm of diameter. Skin was shaved before
injection and cleaned with 70% alcohol solution. Intradermal injections were performed using an
insulin syringe. The injection of Poly ICLC was performed after the I.D. injections of the proteins
and in the middle of each circle with 500 μl injected S.C. This administration procedure was
designed to promote drainage of antigen and adjuvant to the same lymph node site and at the rec-
ommendation of ABL’s head veterinarian. The veterinarian’s report concerning adverse events
from vaccine formulation in the initial vaccinations is shown in S1 text.
Production and quality assurance of αLOX-1.Env gp140
Vectors, cloning strategies, methods for deriving stably transfected CHO-S cells, their culturing
and purification of secreted recombinant antibodies and fusion proteins have been described
previously [29,30]. Specifically, αLOX-1.Env gp140 was derived from the parental anti-human
LOX-1 15C4 recombinant human IgG4 mAb [5,6]; GenBank KM246787 and KM246788) via
humanization of the mouse variable regions (Antitope, Ltd). Env gp140 sequence derived from
the codon optimized HIV-1 96ZM651 synthetic construct (NIH AIDS reagent program, Gen-
Bank AY181197.1 residues 94–2064) was inserted at the IgG4 heavy chain C-terminal codon
distal to a flexV1 flexible linker spacer [30] and proximal to 6 His codons. αLOX-1.Env gp140
was formulated at 0.5 mg/ml in 1 M Arginine 100 mM Tris.HCl pH 7.0 (neutralized protein A
affinity elution buffer) and diluted 1:4 in PBS immediately before injection. In the initial I.D.
vaccinations with αLOX-1.Env gp140 the 1:4 dilution in PBS was not done and grade 5 reac-
tions to the vaccine was noted as pox-like lesions forming within 24–36 hours and then subsid-
ing with the animals being otherwise normal. In subsequent vaccinations, with the 1:4
dilutions in 1xPBS, no similar reactions were observed (the full veterinary report is in S1 Text).
LPS level was 130 pg/mg αLOX-1.Env gp140 protein. Specificity and relative binding affinity of
αLOX-1.Env gp140 to human and Rhesus macaque LOX-1 ectodomains (encoded respectively
by GenBank dbj|AB102861.1| residues 169–918 and ref|NM_001194668.1| residues 295–945)
fused via the cohesin C-terminus (GenBank gb|CP000568.1|residues 3622666–3623172 with a
Nhe I site linker) was confirmed by an adaption of multiplexed Luminex1 bead-based assay
[17].
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Production of NYVAC-KC expressing ZM96gp140, ZM96Gag and
CN54PolNef
NYVAC-KC was constructed as described earlier [31]. A negative selection cassette, PNR, was
inserted into the TK locus of the virus by linear in vivo recombination. The cassette expresses
the coumermycin dimerization domain of Escherichia coli gyrase B fused to the catalytic
domain of mammalian dsRNA-dependent protein kinase, making the virus sensitive to cou-
mermycin (described in [32]) following insertion; also in the cassette is a neomycin resistance
gene. Plaques from the IVR were screened for neomycin resistance to identify viruses contain-
ing the cassette: NYVAC-KC-PNR. The candidate plaque with the greatest coumermycin sen-
sitivity was then amplified for the next step. The plasmids plZAW1-gp140 (96ZM651) and
plZAW1-Gag (96ZM651)-Pol-Nef (CN54) (described in [7], and provided by Ralf Wagner,
University of Regensburg) were then used to insert the genes encoding gp140 and Gag-Pol-
Nef into the TK locus of NYVAC-KC by in vivo recombination. Plaques from the IVR were
screened in coumermycin-treated cells, first for blue color in the presence of β-galactosidase
(lacZ gene in the plasmid, indicating a successful first recombination event to insert the plas-
mid) for two rounds, and then screened for loss of blue and resistance to coumermycin through
two more rounds of plaque purifying (loss of the cassette equals gain of resistance to coumer-
mycin, second recombination event removes plasmid features external to antigen coding,
including the lacZ gene). IVRs were done in BSC-40 cells, stock virus preparation was done in
BHK cells (both cell lines from ATCC), and stocks were 2X sucrose pad-purified. Correct anti-
gen expression was verified by Western blot and Immunoplaque assay and genes were con-
firmed by sequencing. The two viruses, NYVAC-KC-gp140 and NYVAC-KC-GPN, were
combined at a titer of 1x108 pfu each virus per 0.2 ml per vial; contents of each vial were
diluted just prior to inoculation in 1 ml 1X TBS for delivery of 2x108 pfu per animal per 1 ml
inoculation.
Neutralization assay
Neutralization was measured as a function of reductions in luciferase (Luc) reporter gene
expression after a single round of infection in TZM-bl cells as described [32]. TZM-bl cells
were obtained from the NIH AIDS Research and Reference Reagent Program, contributed
by John Kappes and XiaoyunWu. Briefly, test samples were diluted over a range of 1:20 to
1:43740 in cell culture medium and pre-incubated with virus (~150,000 relative light unit
equivalents) for 1 hr at 37°C before addition of cells (10,000 cells in 100 μl of growth medium
containing 75 μg/ml DEAE-dextran). Following incubation for 48 hr, cells were lysed and Luc
activity determined using a micro titer plate luminometer and BriteLite Plus Reagent (Perkin
Elmer). Neutralization titers are the sample dilution (for serum) or antibody concentration (for
sCD4, purified IgG preparations and monoclonal antibodies) at which relative luminescence
units (RLU) were reduced by 50% compared to RLU in virus control wells after subtraction of
background RLU in cell control wells. Serum samples were heat-inactivated at 56°C for 1 hr
prior to assay. Assay stocks of molecularly cloned Env-pseuotyped viruses were prepared by
transfection in 293T cells and were titrated in TZM-bl cells as described [33].
ELISA
Cohesin fusion proteins [30] were expressed in CHO-S cells from vectors containing the above
Env gp140 sequence, or Env fragments (gp120 residues 94–1550; gp41 residues 1551–2064,
inserted between the cohesin domain and 6 C-terminal His codons,). HIV Env-specific IgG
antibody titers in serum from vaccinated animals were assessed at indicated time points post-
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immunization using ELISA. ELISA plates were coated with 2 μg/ml of the cohesin fusion pro-
teins in 0.2 M sodium carbonate-bicarbonate buffer, pH 9.4. Serial dilutions of serum starting
at 1:500 in TBS blocking solution (StartingBlock T20, Pierce) were incubated in the wells over-
night at 4°C. After washing, plates were incubated with HRP-conjugated goat anti-human IgG
(Jackson ImmunoResearch, West Grove, PA) in TBS blocking solution (Thermo Scientific,
Rockford, IL) for 2 h at 37°C, then washed and developed with HRP substrate (TMB, Life
Technologies), stopped with equal volume of 1N HCl and read at 450 nm. The log10 trans-
formed and normalized areas under the curves (AUC) data were calculated for each animal at
each time point using GraphPad Prism 6 software (GraphPad, La Jolla, CA). EC50 calculations
were based on Log10 transformed and normalized data with non-linear regression curve fit
using sigmoidal dose response with variable slope constraints.
HIV-1 specific binding antibody assay
HIV-1 specific IgG antibodies to gp120/gp140 proteins and V1/V2 scaffolds were measured by
an HIV-1 binding antibody multiplex assay [34]. All assays were run under GCLP compliant
conditions, including tracking of positive controls by Levy-Jennings charts using 21CFR Part
11 compliant software. Positive controls included a HIVIG and CH58 mAb IgG titration. Neg-
ative controls included in every assay were blank, MulVgp70_His6 (empty gp70 scaffold) cou-
pled beads, and HIV-1 negative sera. To control for antigen performance, we used the preset
criteria that the positive control titer (HIVIG) included on each assay (and for assays with
V1V2 antigens, CH58 mAb, [35]) had to be within +/- 3 standard deviations of the mean for
each antigen (tracked with a Levy-Jennings plot with preset acceptance of titer (calculated with
a four-parameter logistic equation, SigmaPlot, Systat Software). Antibody measurements were
acquired on a Bio-Plex instrument (Bio-Rad, Hercules, CA) using 21CFR Part 11 compliant
software and the readout is in MFI. The following antigens were examined: (Con S gp140 CF
(a group M consensus envelope gp140; [36, 37], A1.con.env03 140 CF (clade A Consensus), B.
con.env03 140 CF (clade B Consensus), C.con.env03 140 CF (clade C Consensus), ZM96
gp140 (clade C), JRFL gp140, 00MSA 4076 gp140, gp70 control, gp70_B.CaseA2 V1/V2 (a
recombinant
clade B gp70 scaffold protein with the V1V2 variable region), C.1086V1-V2 Tags (a confor-
mational V1-V2 antigen without the MuLV protein from transmitted clade C isolate that cor-
relates with HIV-1 risk [10] provided by Drs. Liao and Haynes, Duke). Criteria for positive
responses are defined below Statistical methods.
Intracellular cytokine staining
Simulations were performed as described [38]. In short, cryopreserved PBMC were thawed
and rested overnight in R10/RPMI 1640 (BioWhittaker, Walkersville, MD), 10% FBS, 2 mM L-
glutamine, 100 U/ml penicillin G, 100 μg/ml streptomycin] with 50 U/ml Benzonase (Novagen,
Madison, WI) in a 37°C/5% CO2 incubator. The following morning, cells were stimulated with
peptide pools (2 μg/ml) in the presence of GogiPlug (10 μg/ml; BD Biosciences, San Jose, Cali-
fornia) for 6 h. Negative controls received an equal concentration of DMSO instead of peptides.
Subsequently, intracellular cytokine staining (ICS) was performed as described [39]. The fol-
lowing monoclonal antibodies were used: CD4-BV421 (clone OKT4; BioLegend), CD8-BV570
(clone RPA-T8; BioLegend), CD69-ECD (clone TP1.55.3; Beckman Coulter), CD3-Cy7APC
(clone SP34.2; BD Biosciences), IFN-γ-APC (clone B27; BD Biosciences), IL-2-PE (clone
MQ1-17H12; BD Biosciences), and TNF-FITC (clone Mab11; BD Biosciences). Aqua LIVE/
DEAD kit (Invitrogen, Carlsbad, CA) was used to exclude dead cells. All antibodies were
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previously titrated to determine the optimal concentration. Samples were acquired on an LSR
II flow cytometer and analyzed using FlowJo version 9.8 (Treestar, Inc., Ashland, OR).
ADCC
ADCC activity against MW965.1 gp120 (provided by the Duke CAVD repository) coated
CEM.NKRCCR5 (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CEM.NKR-
CCR5 from Dr. Alexandra Trkola) target cells was measured using the ADCC-GranToxiLux
(GTL) assay as previously described [40]. ADCC activity against HIV-1 infected cells was mea-
sured using the Luciferase ADCC assay as described [41]. For these assays, the CEM.NKRCCR5
target cells were infected with a replication-competent infectious molecular clone designed to
encode the MW965.LucR.T2A.ecto/293T/17 (accession number U08455) Env gene in cis
within an isogenic backbone that also expresses the Renilla luciferase reporter gene and pre-
serves all viral open reading frames [42]. For both ADCC assay methodologies the effector cells
were PBMC isolated from a HIV-1 seronegative human donor heterozygous for 158F/V poly-
morphic variants of Fcγ receptor 3A. The area under the curve was calculated to evaluate the
impact of the vaccine regimen on the immune responses. For the GTL assay, the non-paramet-
ric area under the net activity percentage vs. dilution curve (AUC) was calculated based on
log10 scale of dilution levels using trapezoid approach. The net activity percentage is calculated
as difference between activity percentage of sample minus activity percentage of background,
divided by % of target cell that are infected: ([Activity %]sample−[Activity %]BKGD)/[TARGET
CELL INFECTED], where [TARGET CELL INFECTED] is set to 100 for coted cells. If the
background activity is greater than the sample activity, the net activity percentage is set to zero
for the sake of area calculation. For the Luc assay, the non-parametric area under the average
percent loss Luciferase activity vs. dilution curve is calculated based on log10 scale of dilution
levels using trapezoid approach. The average percent loss Luciferase activity is the average
value for percent loss of Luciferase activity relative to background control over 2 wells: ([RED-
OUT VALUE]BKG-[READOUT VALUE])/[READOUT VALUE]BKG -, where [READOUT
VALUE]BKG is the average [READOUT VALUE] for wells containing Target and Effector
cells, but no Ab, and [READOUT VALUE] is RLU for sample. If the average percent loss Luc
activity is negative, the value is set to zero for the sake of area calculation.
ELISPOT
Millipore 96 well filtration plates were pre-treated with 70% EtOH, washed 5x with 1x PBS and
then coated with 5 μg/ml mouse-anti-human-IFNγ antibody (BD Pharmingen) over night at
4°C. After blocking with complete RPMI for 2 hours at 37°C, 2x105 PBMCs (prepared as for
ICS) were stimulated in triplicates with peptide pools at 1 μg/ml, or PHA (2.5 μg/ml) as positive
control, while addition of medium only served as negative control. The peptides and peptide
pools used are those described in [43] and are detailed in S4 Table. Plates were incubated at
37°C for 18–24 hours before washing with cold H2O twice and PBS/T for five times. Biotiny-
lated anti-IFNγ-antibody (Mabtech) was added at 1 μg/ml for 1 hour at 37°C and, after wash-
ing, a 1: 2000 dilution of Avidin-HRP (Vector Laboratories) was added, again for 1 hour at
37°C. After final washing, stable DAB (Invitrogen) was added for 2 min, and then the reaction
was stopped with water washing. After drying, the numbers of spots in each well were counted
with an automated ELISPOT reader (CTL Immunospot).
Statistical methods
Wilcoxon signed-rank tests are used to compare change of marker value at specific time points
with baseline within each group. Comparison between groups at specific time points is made
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using the Wilcoxon rank sum test. Response rates are compared between groups using Fisher's
exact test. Overall magnitude of ELISPOT response is compared between groups G1 and G2 by
fitting a random effect model using log transformed data measured after W14. No adjustments
are made for multiple comparisons, as these are exploratory analyses for which increased Type
1 error is tolerated for better sensitivity to detect effects. A p-value of less than or equal to 0.05
is considered statistically significant. Statistical analyses were done with R (version 3.1.2; The R
foundation for Statistical Computing, Vienna, Austria). For the antigen-specific antibody mea-
surements shown in Figs 5 and 6 several criteria are used to determine if data from an assay are
acceptable and can be statistically analyzed. The blood draw rate must be within the allowable
visit window as determined by the protocol. Secondly, if the blank bead negative control
exceeds 5,000 MFI, the sample will be repeated. If the repeat value exceeds 5,000 MFI, the sam-
ple will be excluded from analysis due to high background. QC and standard curve titers must
fall within +/- 3 standard deviations of the historical mean plotted on Levey Jennings charts.
Sample and control replicates must also be within 20% CV. Samples from post-vaccination
time points measured at 1:80 dilution level determined to have a positive binding antibody
response by BAMA if they met three conditions: (1) the MFI minus Blank (MFI) values at
given dilution were greater than or equal to antigen-specific cutoff (based on the average +/- 3
standard deviation of 60 historical sero-negative plasma samples), (2) the MFI values were
greater than 3 times the baseline (day 0) MFI values, and (3) the MFI values were greater than
3 times the baseline MFI values. If a background-subtracted Blank has negative MFI, the value
was replaced by 0. For each antigen and visit, the magnitude of binding response among both
responders and non-responders is compared between groups using the Wilcoxon rank sum
test. Response rates are compared between groups using Fisher's exact test. No adjustments are
made for multiple comparisons, as these are exploratory analyses for which increased Type 1
error is tolerated for better sensitivity to detect effects. A p-value of less than or equal to 0.05 is
considered statistically significant.
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